Page 163 - Read Online

Page 82 Sadaf et al. J Transl Genet Genom 2022;6:63-83 https://dx.doi.org/10.20517/jtgg.2021.36

101. Schuster SR, Kortuem KM, Zhu YX, et al. The clinical significance of cereblon expression in multiple myeloma. Leuk Res
2014;38:23-8. DOI PubMed PMC
102. Mandelbaum J, Bhagat G, Tang H, et al. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse
large B cell lymphoma. Cancer Cell 2010;18:568-79. DOI PubMed PMC
103. Esteve FR, Roodman GD. Pathophysiology of myeloma bone disease. Best Pract Res Clin Haematol 2007;20:613-24. DOI PubMed
104. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple
myeloma. N Engl J Med 2003;349:2483-94. DOI PubMed
105. Qiang YW, Chen Y, Stephens O, et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production
by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 2008;112:196-207. DOI
PubMed PMC
106. Fulciniti M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood
2009;114:371-9. DOI PubMed PMC
107. Cea M, Cagnetta A, Adamia S, et al. Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple
myeloma cells. Blood 2016;127:1138-50. DOI PubMed PMC
108. Song Y, Li S, Ray A, et al. Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes
bortezomib resistance. Oncogene 2017;36:5631-8. DOI PubMed PMC
109. Qin Y, Zhang S, Deng S, et al. Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting
AURKA in multiple myeloma. Leukemia 2017;31:1123-35. DOI PubMed
110. Caracciolo D, Di Martino MT, Amodio N, et al. miR-22 suppresses DNA ligase III addiction in multiple myeloma. Leukemia
2019;33:487-98. DOI PubMed PMC
111. Walker BA, Wardell CP, Chiecchio L, et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of
multiple myeloma. Blood 2011;117:553-62. DOI PubMed
112. Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 2000;355:248-50. DOI PubMed
113. Klein B, Zhang X, Lu Z, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995;85:863-72. PubMed
114. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of
undetermined significance, and normal bone marrow plasma cells. Blood 2002;99:1745-57. DOI PubMed
115. Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via beta1 integrins regulates p27kip1
levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000;19:4319-27. DOI PubMed
116. Mohty M, Harousseau JL. Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and
answers. Haematologica 2014;99:408-16. DOI PubMed PMC
117. Hideshima T, Raje N, Richardson PG, Anderson KC. A review of lenalidomide in combination with dexamethasone for the treatment
of multiple myeloma. Ther Clin Risk Manag 2008;4:129-36. DOI PubMed PMC
118. Weber DM, Chen C, Niesvizky R, et al; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed
multiple myeloma in North America. N Engl J Med 2007;357:2133-42. DOI PubMed
119. Abramson HN. Monoclonal antibodies for the treatment of multiple myeloma: an update. Int J Mol Sci 2018;19:3924. DOI PubMed
PMC
120. Ito S. Proteasome inhibitors for the treatment of multiple myeloma. Cancers (Basel) 2020;12:265. DOI PubMed PMC
121. Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2020;20:1-7. DOI
PubMed
122. Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal
antibody therapy. Leukemia 2019;33:2266-75. DOI PubMed PMC
123. Gerrie AS, Mikhael JR, Cheng L, et al. D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma. Br J Haematol
2013;161:802-10. DOI PubMed
124. Griffin PT, Ho VQ, Fulp W, et al. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple
myeloma. Cancer 2015;121:3622-30. DOI PubMed
125. Michael M, Bruns I, Bölke E, et al. Bendamustine in patients with relapsed or refractory multiple myeloma. Eur J Med Res
2010;15:13-9. DOI PubMed PMC
126. Lau IJ, Smith D, Aitchison R, et al. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in
myeloma relapsed and/or refractory to bortezomib and lenalidomide. Ann Hematol 2015;94:643-9. DOI PubMed
127. Ludwig H, Kasparu H, Leitgeb C, et al. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients
with relapsed or refractory multiple myeloma. Blood 2014;123:985-91. DOI PubMed PMC
128. San-miguel JF, Hungria VTM, Yoon S, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and
dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase
3 trial. Lancet Oncol 2014;15:1195-206. DOI PubMed
129. Richardson PG, Schlossman RL, Alsina M, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone
in patients with relapsed and bortezomib-refractory myeloma. Blood 2013;122:2331-7. DOI PubMed
130. Siegel DS, Dimopoulos M, Jagannath S, et al. VANTAGE 095: an international, multicenter, open-label study of vorinostat (MK-
0683) in combination with bortezomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk
2016;16:329-34.e1. DOI PubMed
131. Dimopoulos M, Siegel DS, Lonial S, et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma
(VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol 2013;14:1129-40. DOI PubMed